Ajamodadi Churna: Benefits, Evidence, Dosage & Safety

By Swastik Research Desk · Editorial review: Swastik Research Desk · Last updated: September 19, 2026

TL;DR

Ajamodadi churna is a classical Ayurvedic powder of 12 ingredients (ajamoda, vidanga, and chitraka among them), standardized in the Ayurvedic Formulary of India. The evidence file is thin: one peer-reviewed animal study found anti-inflammatory effects in rats, and the human evidence is a handful of small, low-quality clinical reports. No benefit in people is proven.

What it is

Ajamodadi churna is a classical Ayurvedic polyherbal powder. A pharmaceutical standardization paper traces its formulary formula to the Sharangadhara Samhita (Madhyama Khanda): 12 ingredients, namely Ajamoda, Vidanga, Saindhava lavana (rock salt), Devadaru, Chitraka, Pippalimula, Shatapushpa, Pippali, Maricha, Pathya, Vriddhadaru, and Nagara (JBSO paper). A peer-reviewed pharmacological study prepared the formulation according to the Ayurvedic Formulary of India (AFI) (J-AIM). The Government of India lists the AFI among its official formulary and pharmacopoeial publications (Parliament of India), and a scan of AFI Part II, which covers 191 classical formulations, sits in a public archive (AFI Part II scan).

One naming wrinkle, because Ayurveda loves those: the key herb ajamoda is Trachyspermum roxburghianum, while older literature uses the synonym Carum roxburghianum. Same plant, different name, depending on which paper you are reading.

Traditional use

Classical Ayurvedic literature uses this powder for amavata, a joint disorder that modern papers usually gloss as resembling rheumatoid arthritis, and for digestive complaints tied to weak digestive fire (JAIMS; JBSO paper). That is traditional use, recorded in texts and formulary literature. It is not clinical proof the powder works. I want that distinction nailed down before anyone reads the research section as validation.

What modern research says, by benefit

Inflammation — animal evidence only

In the Journal of Ayurveda and Integrative Medicine, researchers gave rats an aqueous extract of ajamodadi churna and measured two standard inflammation models: carrageenan-induced paw edema and the air-pouch model. Swelling and inflammatory measures fell (J-AIM). A real result in rats. The authors themselves wrote that human clinical evaluation was still needed, which is the responsible thing to say. Here is the blunter version: animal results of this kind cannot establish benefit in people. They never could.

Joint symptoms (amavata-like) — weak human data

The human literature is three studies, and I would not lean on any of them. An uncontrolled 2015 clinical report gave 3 g twice daily before meals for three months to people with amavata. No control group, small sample, so it cannot demonstrate efficacy (IAMJ). A randomized comparative study of 40 people tested ajamodadya churna at 3 g twice daily after food for one month against another Ayurvedic powder. Small, two active treatments with no placebo arm, limited reporting (JAIMS). A 2020 single-group study combined the churna with Vaitaran Basti, a medicated enema, so whatever happened cannot be credited to the powder (JETIR). Three studies, three reasons to withhold judgment.

Digestion — no direct modern evidence found

I found no peer-reviewed clinical or experimental studies testing ajamodadi churna itself for digestive outcomes. None. Digestive claims rest on traditional use, not on measured results. Short section. That is the point.

Dosage

The published trials used 3 g twice daily: before meals for three months in the uncontrolled amavata report (IAMJ), and after food with lukewarm water for one month in the 40-person randomized comparative study (JAIMS). Read that sentence as history, not advice. These were research regimens in small, low-quality studies, not established recommendations. No pharmacopoeial monograph or high-quality trial establishes a standard dose, so no personal dose belongs in this article. A qualified Ayurvedic practitioner should individualize any use.

Safety

Published human safety data on ajamodadi churna are sparse. That is the headline, and the rest follows from it. With no formulation-specific safety studies, the powder should not be assumed safe during pregnancy, while breastfeeding, in children, or alongside other medicines. Use only under the guidance of a qualified practitioner. I am keeping this section short on purpose: there is no data to dress up.

FAQs

What is ajamodadi churna?

A classical Ayurvedic polyherbal powder of 12 ingredients, ajamoda, vidanga, chitraka, pippali, maricha, devadaru, and rock salt among them, with its formula deriving from the Sharangadhara Samhita and standardized in the Ayurvedic Formulary of India (JBSO paper; J-AIM). Traditionally used for joint disorders and digestive complaints. Neither use is clinically proven, and I would not let the word "classical" do the work of evidence.

What is ajamoda, the main herb?

The principal herb of the formulation. It is given as Trachyspermum roxburghianum, though older literature uses the synonym Carum roxburghianum, so the name varies across sources. Traditionally valued as a carminative, a gas-relieving herb. The synonym issue is worth remembering: different sources may describe slightly different plants under the same name.

Does it help joint pain or arthritis?

There is no reliable human evidence that it does. The supportive data are one peer-reviewed animal study showing reduced inflammation in rats, which cannot prove benefit in people, plus small, uncontrolled or weakly controlled human reports (J-AIM; JAIMS). The animal-study authors themselves said human clinical evaluation was still needed. I agree with them.

What dose was used in studies?

3 g twice daily in the published reports: before meals for three months in an uncontrolled amavata report, and after food with lukewarm water for one month in a small randomized comparative study (IAMJ; JAIMS). Study regimens from low-quality research. Not established doses. Do not self-prescribe; a qualified Ayurvedic practitioner should decide any dose.

Is it safe during pregnancy?

No published human safety studies of this formulation were found, and I could not locate pregnancy-specific safety data either. Absence of evidence is not evidence of safety. It should not be assumed safe in pregnancy or while breastfeeding. Use only if a qualified practitioner advises it after a personal assessment.

Can I take it alongside other medicines?

There are no published interaction studies for this formulation. Combining it with prescription or over-the-counter medicines carries unknown risks. Unknown, not zero. Discuss everything you take with a qualified Ayurvedic practitioner and your physician before use.

Sources

Tier 1 — Government/official. The Ayurvedic Formulary of India, Part II (Ministry of Health & Family Welfare; institutional scan) (archive.org). The Government of India's parliamentary summary of official formulary and pharmacopoeial publications (sansad.in).

Tier 1 — Peer-reviewed journals / academic. The pharmaceutical standardization paper on the AFI-derived formula (Sharangadhara Samhita, 12 ingredients) (jbsoweb.com). The anti-inflammatory study of aqueous Ajamodadi extract in rat models (J. Ayurveda Integr. Med.) (PMC · PMC3326793). The randomized comparative study of 40 patients, Ajamodadya Churna 3 g twice daily for one month (JAIMS) (jaims.in). The uncontrolled 2015 clinical report, 3 g twice daily before meals for three months in amavata (IAMJ) (d2z1jgbdsyo9jj.cloudfront.net). And the 2020 single-group study combining Ajamodadi Churna with Vaitaran Basti (JETIR) (jetir.org).

This article is educational only and is not medical advice. The evidence for Ajamodadi churna is limited and does not establish any health benefit. Consult a qualified Ayurvedic practitioner or physician before using it.